PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Both companies show declining cash positions (-5.12% vs TRAW's -7.26%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Cash + STI yoy 0.5-0.75x TRAW's -7.26%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Other current assets growth < half of TRAW's -63.92%. David Dodd sees a leaner approach to short-term items.
-4.22%
0.5-0.75x TRAW's -7.52%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-17.65%
≥ 1.5x TRAW's -9.52%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRAW and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x TRAW's -16.67%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-47.54%
≥ 1.5x TRAW's -11.11%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
0.5-0.75x TRAW's -7.52%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
46.70%
Less than half of TRAW's -31.93%. David Dodd sees a more disciplined AP approach or lower volume.
-26.38%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
126.45%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
265.71%
Exceeding 1.5x TRAW's 2.90%. Michael Burry suspects ballooning short-term obligations vs. competitor.
63.25%
Less than half of TRAW's -12.95%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Above 1.5x TRAW's -1.70%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Less than half of TRAW's -9.36%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
≥ 1.5x TRAW's -0.85%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
1.25-1.5x TRAW's -7.14%. Bruce Berkowitz notes an above-average equity expansion.
-4.84%
0.5-0.75x TRAW's -7.52%. Martin Whitman sees underexpansion or possible missed opportunities.
-100.00%
Both TRAW and the company show zero Total Investments Growth.
-26.37%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
5.01%
50-75% of TRAW's 7.26%. Bruce Berkowitz notes comparatively lower net debt expansion.